New Approaches to the Treatment of Dopamine Blocking Agent-Induced Movement Disorders

INTRODUCTION Movement disorders are commonly seen in both neurological and psychiatric practice. Dopamine receptor blocking agents (DRBA) are the most common cause of drug-induced movement disorders. These agents are commonly referred to as neuroleptics, a term coined by Deniker which means ‘‘that which takes on the neuron’’ [1]. In addition to antipsychotic drugs, other agents such as antiemetic drugs and metoclopramide are also included in this category due to their blockade of dopamine receptors. For the assessment of DRBA-inducedmovement disorders a good knowledge of the classification of these disorders is essential.